Zepteon

Zepteon is a privately held corporation that develops purification tools capable of separating antibodies with specific sugar structures.

Zepteon is a privately held corporation that develops purification tools capable of separating antibodies with specific sugar structures, which are more potent against diseases like cancer. The corporation’s chromatography resins are being used to prepare material to evaluate the effects of a wide range of nonfucosylation levels in studies of antibody function. Its technology is also being used analytically, to determine antibody nonfucosylation levels as a function of cell culture conditions. Zepteon’s technology has the ability to support preparation of a biosimilar antibody filing, increasing the chances of regulatory success and increasing speed to market. Zepteon was founded in 2012 by [Austin W. Boesch](https://www.crunchbase.com/person/austin-w--boesch) and [Glen R. Bolton](https://www.crunchbase.com/person/dr-glen-r--bolton#/entity). It is based in Boston, M.A.